Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $61.27, for a total transaction of $490,160.00. Following the completion of the sale, the chief financial officer now owns 95,679 shares of the company’s stock, valued at $5,862,252.33. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Andrew Guggenhime also recently made the following trade(s):

• On Monday, March 18th, Andrew Guggenhime sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $69.02, for a total transaction of $552,160.00.

Vaxcyte Stock Up 1.3 %

Shares of Vaxcyte stock opened at $61.60 on Tuesday. The firm has a market cap of $6.70 billion, a PE ratio of -14.92 and a beta of 0.89. Vaxcyte, Inc. has a 52 week low of $41.57 and a 52 week high of $82.04. The business’s fifty day simple moving average is $69.09 and its 200-day simple moving average is $61.21.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($1.82) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.89) by ($0.93). During the same quarter last year, the firm earned ($0.73) EPS. As a group, equities analysts expect that Vaxcyte, Inc. will post -4.18 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PCVX. Westfield Capital Management Co. LP acquired a new stake in Vaxcyte during the 3rd quarter worth approximately $51,180,000. Norges Bank acquired a new stake in Vaxcyte during the fourth quarter worth approximately $57,494,000. Vestal Point Capital LP purchased a new stake in shares of Vaxcyte during the 4th quarter worth approximately $32,970,000. Eventide Asset Management LLC acquired a new position in shares of Vaxcyte in the 3rd quarter valued at $20,035,000. Finally, First Turn Management LLC purchased a new position in shares of Vaxcyte in the 4th quarter valued at $22,453,000. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PCVX has been the subject of several recent research reports. Bank of America increased their price target on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Vaxcyte in a report on Friday, January 12th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $95.00 price objective on shares of Vaxcyte in a report on Wednesday, April 10th. Four equities research analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte currently has a consensus rating of “Buy” and a consensus target price of $78.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.